Publications by authors named "Y Ashur"
Article Synopsis
- Treatment of chronic hepatitis C (HCV) with direct-acting antivirals (DAAs) can improve liver fibrosis, with 57% of patients showing improvement after at least three years post-treatment.
- A study of 209 patients revealed that factors like age at treatment and advanced fibrosis stage were significantly linked to the regression of fibrosis.
- While 71% of patients were treatment-naïve, 28% experienced significant improvement, moving from advanced fibrosis stages (F3/F4) to lower stages (F2 or less).
The advent of direct-acting antivirals (DAAs) has transformed the landscape of hepatitis C virus (HCV) management. We aimed to prospectively (real-time) evaluate the feasibility of using a response-guided therapy approach, based on mathematical modeling of early viral kinetics, to reduce the duration of DAAs therapy. Patients were treated with DAAs according to the physicians' preference.
View Article and Find Full Text PDFBackground: Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials.
Aim: To determine the effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response.
Unlabelled: We evaluated the vertical transmission of hepatitis B virus (HBV) in the vaccine era after 1992.
Methods: A cross-sectional descriptive study was conducted in the year 2005-2006 at Clalit Health Services, Jerusalem. Children at age > or = 1 year born after 1992, with HBsAg positive mothers, were evaluated.
Background/aims: HCV-AB68, a human monoclonal antibody against the envelope protein of hepatitis C virus (HCV), neutralizes HCV in cell-culture and in the HCV-Trimera mouse model. A Phase 1 clinical trial was designed to test safety, tolerability, and antiviral activity of HCV-AB68 in patients with chronic HCV-infection.
Methods/results: Single doses of HCV-AB68, 0.